hormone use with cyberknife

tibby5368 Member Posts: 2
edited May 2014 in Prostate Cancer #1

i have been told i need a hormone shot with my cyberknife radiation is this needed,my gleason score is 4+3 one asap suspicious,one hgpin,one pti, core where.Doctor said i was intermediate.is a hormone shot with cyberknive agood idea.my age is 65,my prostate size is 4.8,12 cores were taken,psa is4.29,core where cancer active 40% involved 15% of2 of three cores


  • hopeful and optimistic
    hopeful and optimistic Member Posts: 2,333 Member
    Generally No

    Check out the discussion site at cyberknife.com .


    There are doctors at that site, who administer this procedure as will as other knowledgeable lay people who will answer your question.

    Good idea to include the details of your case, that is number of cores, gleason scores, other history so you can receive a best answer. All cases are not the same.

  • tibby5368
    tibby5368 Member Posts: 2
    i should say my gleason score

    i should say my gleason score is 7 with one aera active and two questionable

  • hopeful and optimistic
    hopeful and optimistic Member Posts: 2,333 Member
    tibby5368 said:

    i should say my gleason score

    i should say my gleason score is 7 with one aera active and two questionable

    Some questions

    What is your age?

    Hosw many cores were taken?

    What was the involvement of the core that was positive, that is what percent was cancerous?

    What is the size of your prostate?

    What is your PSA?

    What led to you getting a biopsy?

  • VascodaGama
    VascodaGama Member Posts: 3,513 Member
    Combo therapy: HT + RT


    Welcome to the board.

    CK is just one modality for administering radiotherapy. Radiation “destroys” cell’s DNA, killing them and making them impossible to replicate. The cells are affected when dividing while in their life cycle. Cancerous cells are more active and divide faster which make them more propitious to be killed when radiation is applied. Benign ones take longer in their life cycle phases so that the ones not affected will continue its phases in the cycle surviving the treatment.

    The hormonal treatment (HT) affects cells’ androgen receptors. In trials it has been found that these become more sensitized under HT which leads them to “absorb” radiation better. There have been studies indicating 30 to 35 % improvements in radiotherapies outcomes when these are administered as adjuvant to HT (combo treatments).

    Here is a link that may help you understand the reason behind the success;


    For radiation therapy principles read this;



    Best wishes and luck in your journey.

    VGama    Smile


  • hopeful and optimistic
    hopeful and optimistic Member Posts: 2,333 Member
    some studies , pub med and dr katz publish






    Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

    Alan J Katz, Michael Santoro, Fred Diblasio and Richard Ashley

    For all author emails, please log on.

    Radiation Oncology 2013, 8:118 doi:10.1186/1748-717X-8-118

    Published: 13 May 2013

    Abstract (provisional)


    Stereotactic body radiotherapy (SBRT) may yield disease control for prostate cancer in a brief, hypofractionated treatment regimen without increasing treatment toxicity. Our report presents a 6-year update from 304 low- (n = 211), intermediate- (n = 81), and high-risk (n = 12) prostate cancer patients who received CyberKnife SBRT.


    The median PSA at presentation was 5.8 ng/ml. Fifty-seven patients received neoadjuvant hormonal therapy for up to one year. The first 50 patients received a total dose of 35 Gy in 5 fractions of 7 Gy. The subsequent 254 patients received a total dose of 36.25 Gy in 5 fractions of 7.25 Gy. Toxicity was assessed with the Expanded Prostate Cancer Index Composite questionnaire and the Radiation Therapy Oncology Group urinary and rectal toxicity scale. Biochemical failure was assessed using the nadir + 2 definition.


    No patients experienced Grade III or IV acute complications. Fewer than 5% of patients experienced any acute Grade II urinary or rectal toxicities. Late urinary Grade II complications were observed in 4% of patients treated to 35 Gy and 9% of patients treated to 36.25 Gy. Five (2%) late Grade III urinary toxicities occurred in patients who were treated with 36.25 Gy. Late Grade II rectal complications were observed in 2% of patients treated to 35 Gy and 5% of patients treated to 36.25 Gy. Bowel and urinary quality of life (QOL) scores initially decreased, but later returned to baseline values. An overall decrease of 20% in the sexual QOL score was observed. QOL in each domain was not differentially affected by dose. For patients that were potent prior to treatment, 75% stated that they remained sexually potent. Actuarial 5-year biochemical recurrence-free survival was 97% for low-risk, 90.7% for intermediate-risk, and 74.1% for high-risk patients. PSA fell to a median of 0.12 ng/ml at 5 years; dose did not influence median PSA levels.


    In this large series with long-term follow-up, we found excellent biochemical control rates and low and acceptable toxicity, outcomes consistent with those reported for from high dose rate brachytherapy (HDR BT). Provided that measures are taken to account for prostate motion, SBRT's distinct advantages over HDR BT include its noninvasiveness and delivery to patients without anesthesia or hospitalization.